STADA Arzneimittel AG (ETR:SAZ) has received a consensus rating of “Sell” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation and one has issued a hold recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is €74.74 ($86.91).
Separately, Cfra set a €70.00 ($81.40) target price on STADA Arzneimittel and gave the stock a “sell” rating in a report on Friday, August 10th.
Shares of SAZ traded down €0.06 ($0.07) on Tuesday, hitting €81.66 ($94.95). The company’s stock had a trading volume of 36,120 shares, compared to its average volume of 51,761. STADA Arzneimittel has a fifty-two week low of €53.41 ($62.10) and a fifty-two week high of €90.24 ($104.93).
STADA Arzneimittel Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.